Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Immuno-Oncology: Sneak Peek Of Preclinical Candidates Waiting In The Wings

Executive Summary

Which immuno-oncology candidates are poised to begin their first-in-human clinical trials? How many sponsors already have partners or collaborators? What oncology indications have been proposed? And where will these trials take place? Citeline's Rachel L. Meighan-Mantha has the data.

You may also be interested in...



Finance Watch: Pandion's $55m Series A Funds Localized Bispecifics For Autoimmune Diseases

Pandion, led by former Pfizer SVP Anthony Coyle, launched in 2017 to exploit immuno-oncology advances for autoimmune and inflammatory diseases; the firm's Series A follows a record-breaking year for biopharma venture capital. In public company financings, AveXis and others seek cash to fuel R&D.

Gritstone Grabs $92.7m To Test Personalized Vaccines In Humans

Gritstone closed a Series B venture capital financing to advance its immunotherapy based on cancer patients' own neoantigens into clinical testing and to explore a new shared antigen platform.

BMS Scoops Cormorant In $520M Immuno-Oncology Deal

Bristol-Myers Squibb Co. has bolstered its immuno-oncology ambitions by acquiring IL-8 focused Cormorant Pharmaceuticals AB, the 4-year old Swedish biotech. Cormorant’s shareholders are getting $95M up front with the promise of a further $425M if milestones are achieved.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel